Goldman Sachs initiated coverage of Tyra Biosciences (TYRA) with an Early-Stage Biotech rating. Tyra is a clinical stage biotechnology company using its proprietary drug-discovery platform to develop precision medicines to address significant unmet need, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA: